TCS Introduces Agentic AI Platform to Revolutionize Drug Development

In August 2026, Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions, introduced TCS ADDTM AgentHub, a role-based, enterprise-ready, and trusted AI platform that facilitates the application of agentic AI in drug development at scale. This innovative workforce transforms clinical trials and pharmacovigilance services while adhering to regulatory and audit requirements.

Pharmaceutical companies operate in highly regulated environments and face significant challenges related to trust, governance, and scalability when implementing AI across functions. The growing volume of data, fragmented systems, and increasing regulatory expectations surrounding clinical development and pharmacovigilance complicate the entire R&D value chain.

TCS ADDTM AgentHub provides a structured framework to address these challenges. Within this framework, AI agents can function with clearly defined roles, oversight, and built-in auditability. Pharmaceutical organizations can customize their AI agent hubs and deploy them across clinical workflows, allowing for rapid and streamlined integration with minimal effort, thereby accelerating adoption while ensuring regulatory compliance.

Anchored in the TCS ADDTM framework, TCS ADDTM AgentHub delivers measurable operational benefits across drug development and drug safety functions. Solutions powered by this platform have demonstrated efficiency gains of up to 40% in clinical data management activities, a reduction of up to 30% in clinical study build effort through metadata-driven automation, and cost savings of up to 30% in end-to-end safety case processing. AI-powered safety agents can also significantly reduce quality control efforts by as much as 50%, enhancing productivity across critical R&D processes.

Debashis Ghosh, President of Life Sciences and Healthcare at TCS, stated, “TCS ADDTM AgentHub is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It facilitates a transition from reactive to proactive, scalable, and audit-ready operations amid an evolving regulatory landscape. TCS’ strategy aims to evolve toward autonomous enterprise functions where an agentic AI workforce collaborates with humans, driving innovation in drug development and improving patient safety.”

Impact on the Pharmacovigilance Market

The global pharmacovigilance market size was estimated at USD 10.36 billion in 2025 and is expected to reach over USD 23.92 billion by 2035, growing at a CAGR of 8.73% from 2026 to 2035.

According to precedence research, the growing applications of AI in the pharmaceuticals and healthcare industries have led to the adoption of AI in the pharmacovigilance market. AI technology helps in the detection and assessment of potential adversities by detecting patterns through analysis of a large amount of data from various sources.

This launch is transforming the pharmacovigilance industry. TCS ADDTM AgentHub helps workflows across clinical development and pharmacovigilance through AI workers such as ICSR intake, coding, data entry, review, and literature analysis, study design, protocol digitization, and clinical data review, SDTM (Study Data Tabulation Model) transformation and medical monitoring assistance, among others. With a changing catalogue of AI agents to suit specific needs, based on needs and landscape, they can be deployed progressively and rapidly with minimal integration and implementation effort.

Impact on the AI in Pharmaceutical Market

The global AI in pharmaceutical market size was valued at USD 1.94 billion in 2025 and is expected to grow from USD 2.51 billion in 2026 to approximately USD 18.99 billion by 2035, expanding at a CAGR of 25.62% from 2026 to 2035.

According to precedence research, the launch of TCS ADDTM AgentHub is expanding AI in the pharmaceutical industry. By harnessing the power of AI, pharmaceutical companies can rapidly advance the future of healthcare. AI can significantly improve the operations related to manufacturing, clinical trials, and research & development.

Built on the TCS ADDTM agentic AI architecture, TCS ADDTM AgentHub allows pharma companies to deploy a Human + AI Operating Model in which AI agents are embedded into enterprise workflows, with humans retaining responsibility for governing and decision‑making.

About TCS

Tata Consultancy Services (TCS) is the technology partner of choice for industry-leading organizations globally. Since its inception in 1968, TCS has upheld the highest standards of innovation, engineering excellence, and consumer service.  Rooted in the heritage of the Tata Group, TCS has emphasized developing long-term value for its clients, its investors, its employees, and the community at large. It aspires to be the world's largest AI-led technology services company and is enabling its clients to change themselves across the full AI stack, from infrastructure to intelligence. With a highly skilled workforce spanning 55 countries and 202 service delivery centers across the globe, the company has been recognized as a top employer in six continents.